Cargando…

Prognostic value of normal sodium levels in patients with metastatic renal cell carcinoma receiving tyrosine kinase inhibitors

BACKGROUND: Although serum sodium concentration, particularly hyponatremia, has been shown to be a prognostic marker of survival in metastatic renal cell carcinoma (mRCC), the impact of normal sodium levels has not been investigated. Herein, we investigate the influence of normonatremia in mRCC pati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Roviello, Giandomenico, Catalano, Martina, De Giorgi, Ugo, Maruzzo, Marco, Buti, Sebastiano, Gambale, Elisabetta, Procopio, Giuseppe, Ottanelli, Carlotta, Caliman, Enrico, Isella, Luca, Sepe, Pierangela, Brighi, Nicole, Santoni, Matteo, Galli, Luca, Conca, Raffaele, Doni, Laura, Antonuzzo, Lorenzo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9424544/ https://www.ncbi.nlm.nih.gov/pubmed/36052244 http://dx.doi.org/10.3389/fonc.2022.918413

Ejemplares similares

Long-Term Response to Tyrosine Kinase Inhibitors for Metastatic Renal Cell Carcinoma
por: Catalano, Martina, et al.
Publicado: (2022)

BONSAI-2 study: Nivolumab as therapeutic option after cabozantinib failure in metastatic collecting duct carcinoma patients
por: Buti, Sebastiano, et al.
Publicado: (2022)

Effect of systemic therapies or best supportive care after disease progression to both nivolumab and cabozantinib in metastatic renal cell carcinoma: The Meet‐Uro 19BEYOND study
por: Roviello, Giandomenico, et al.
Publicado: (2022)

Clinical outcome of renal cancer patients who early interrupted immunotherapy due to serious immune-related adverse events. Meet-Uro 13 trial on behalf of the MeetUro investigators
por: Stellato, Marco, et al.
Publicado: (2021)

Lung Cancer Immunotherapy: Beyond Common Immune Checkpoints Inhibitors
por: Catalano, Martina, et al.
Publicado: (2022)

The impact of proton-pump inhibitors administered with tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma
por: Buti, Sebastiano, et al.
Publicado: (2022)

Immune checkpoint blockade with anti-programmed cell death 1 (PD-1) monoclonal antibody (mAb) cemiplimab: ongoing and future perspectives in rare genital cancers treatment
por: Gambale, Elisabetta, et al.
Publicado: (2022)

The role of mean corpuscular volume and red cell distribution width in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors: the MARECAP retrospective study
por: Tommasi, Chiara, et al.
Publicado: (2023)

Neoadjuvant Treatment in Muscle-Invasive Bladder Cancer: From the Beginning to the Latest Developments
por: Roviello, Giandomenico, et al.
Publicado: (2022)

Antiangiogenic tyrosine kinase inhibitors and immunotherapy as first-line treatment for metastatic renal cell carcinoma: is there an increased risk of hypothyroidism?
por: Roviello, Giandomenico, et al.
Publicado: (2021)

Beyond Conventional: The New Horizon of Targeted Therapy for the Treatment of Advanced Non Small Cell Lung Cancer
por: Tartarone, Alfredo, et al.
Publicado: (2021)

Liquid biopsy in colorectal cancer: No longer young, but not yet old
por: Roviello, Giandomenico, et al.
Publicado: (2022)

Safety of Immune Checkpoint Inhibitors in Elderly Patients: An Observational Study
por: Paderi, Agnese, et al.
Publicado: (2021)

Sodium Levels and Outcomes in Patients With Metastatic Renal Cell Carcinoma Receiving Nivolumab
por: Catalano, Martina, et al.
Publicado: (2023)

FOLFOX vs FOLFIRI as Second-line of Therapy After Progression to Gemcitabine/Nab-paclitaxel in Patients with Metastatic Pancreatic Cancer
por: Catalano, Martina, et al.
Publicado: (2020)

A multicenter phase 2 single arm study of cabozantinib in patients with advanced or unresectable renal cell carcinoma pre-treated with one immune-checkpoint inhibitor: The BREAKPOINT trial (Meet-Uro trial 03)
por: Procopio, Giuseppe, et al.
Publicado: (2022)

Association between Low-Grade Chemotherapy-Induced Peripheral Neuropathy (CINP) and Survival in Patients with Metastatic Adenocarcinoma of the Pancreas
por: Catalano, Martina, et al.
Publicado: (2021)

The impact of age, performance status and comorbidities on nab-paclitaxel plus gemcitabine effectiveness in patients with metastatic pancreatic cancer
por: Catalano, Martina, et al.
Publicado: (2022)

Impact of Previous Nephrectomy on Clinical Outcome of Metastatic Renal Carcinoma Treated With Immune-Oncology: A Real-World Study on Behalf of Meet-URO Group (MeetUro-7b)
por: Stellato, Marco, et al.
Publicado: (2021)

Application of the Meet-URO score to metastatic renal cell carcinoma patients treated with second- and third-line cabozantinib
por: Rebuzzi, Sara Elena, et al.
Publicado: (2022)

Immunotherapeutic Targets and Therapy for Renal Cell Carcinoma
por: Sepe, Pierangela, et al.
Publicado: (2020)

Prognostic Value of Thyroid Hormone Ratio in Patients With Advanced Metastatic Renal Cell Carcinoma: Results From the Threefour Study (Meet-URO 14)
por: Maruzzo, Marco, et al.
Publicado: (2021)

Editorial: Microbiota and metabolites in cancer immunotherapy
por: Roviello, Giandomenico, et al.
Publicado: (2022)

Evaluation of Fruquintinib in the Continuum of Care of Patients with Colorectal Cancer
por: Lavacchi, Daniele, et al.
Publicado: (2023)

Immune checkpoint inhibitor induced nephrotoxicity: An ongoing challenge
por: Catalano, Martina, et al.
Publicado: (2022)

Correlation Between Tumor Response and Survival Outcomes in Patients with Advanced Gastric Cancer Receiving Ramucirumab and Paclitaxel as Second-Line Therapy
por: Roviello, Giandomenico, et al.
Publicado: (2022)

Characteristics and Treatment Challenges of Non-Clear Cell Renal Cell Carcinoma
por: Sepe, Pierangela, et al.
Publicado: (2021)

Outcome of oligoprogressing metastatic renal cell carcinoma patients treated with locoregional therapy: a multicenter retrospective analysis
por: Santini, Daniele, et al.
Publicado: (2017)

Risk of recurrence and conditional survival in complete responders treated with TKIs plus or less locoregional therapies for metastatic renal cell carcinoma
por: Santini, Daniele, et al.
Publicado: (2016)

Navigating the Rapidly Evolving Advanced Urothelial Carcinoma Treatment Landscape: Insights from Italian Experts
por: Santini, Daniele, et al.
Publicado: (2023)

Immune Modulation in Prostate Cancer Patients Treated with Androgen Receptor (AR)-Targeted Therapy
por: Conteduca, Vincenza, et al.
Publicado: (2020)

Immune combinations and complete response: a new hope for metastatic renal cell carcinoma
por: Catalano, Martina, et al.
Publicado: (2022)

Perioperative Tailored Treatments for Gastric Cancer: Times Are Changing
por: Lavacchi, Daniele, et al.
Publicado: (2023)

Mutations matter: An observational study of the prognostic and predictive value of KRAS mutations in metastatic colorectal cancer
por: Lavacchi, Daniele, et al.
Publicado: (2022)

Is there a preferred first-line therapy for metastatic renal cell carcinoma? A network meta-analysis
por: Cattrini, Carlo, et al.
Publicado: (2021)

The prognostic value of baseline and early variations of peripheral blood inflammatory ratios and their cellular components in patients with metastatic renal cell carcinoma treated with nivolumab: The Δ-Meet-URO analysis
por: Rebuzzi, Sara Elena, et al.
Publicado: (2022)

The prognostic value of the previous nephrectomy in pretreated metastatic renal cell carcinoma receiving immunotherapy: a sub-analysis of the Meet-URO 15 study
por: Rebuzzi, Sara Elena, et al.
Publicado: (2022)

Pembrolizumab Plus Axitinib for Metastatic Papillary and Chromophobe Renal Cell Carcinoma: NEMESIA (Non Clear MEtaStatic Renal Cell Carcinoma Pembrolizumab Axitinib) Study, a Subgroup Analysis of I-RARE Observational Study (Meet-URO 23a)
por: Stellato, Marco, et al.
Publicado: (2023)

Gut Microbiota Modulation in the Context of Immune-Related Aspects of Lactobacillus spp. and Bifidobacterium spp. in Gastrointestinal Cancers
por: Kaźmierczak-Siedlecka, Karolina, et al.
Publicado: (2021)

Enfortumab vedotin in metastatic urothelial carcinoma: the solution EVentually?
por: Maiorano, Brigida Anna, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_vc7edibrk23pve6o5makrh3h5n